Published online Dec 24, 2015. doi: 10.5500/wjt.v5.i4.209
Peer-review started: July 3, 2015
First decision: July 30, 2015
Revised: August 23, 2015
Accepted: September 25, 2015
Article in press: September 28, 2015
Published online: December 24, 2015
Processing time: 176 Days and 21.2 Hours
Several diseases have been successfully modeled since the development of induced pluripotent stem cell (iPSC) technology in 2006. Since then, methods for increased reprogramming efficiency and cell culture maintenance have been optimized and many protocols for differentiating stem cell lines have been successfully developed, allowing the generation of several cellular subtypes in vitro. Gene editing technologies have also greatly advanced lately, enhancing disease-specific phenotypes by creating isogenic cell lines, allowing mutations to be corrected in affected samples or inserted in control lines. Neurological disorders have benefited the most from iPSC-disease modeling for its capability for generating disease-relevant cell types in vitro from the central nervous system, such as neurons and glial cells, otherwise only available from post-mortem samples. Patient-specific iPSC-derived neural cells can recapitulate the phenotypes of these diseases and therefore, considerably enrich our understanding of pathogenesis, disease mechanism and facilitate the development of drug screening platforms for novel therapeutic targets. Here, we review the accomplishments and the current progress in human neurological disorders by using iPSC modeling for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, duchenne muscular dystrophy, schizophrenia and autism spectrum disorders, which include Timothy syndrome, Fragile X syndrome, Angelman syndrome, Prader-Willi syndrome, Phelan-McDermid, Rett syndrome as well as Nonsyndromic Autism.
Core tip: Several diseases have been successfully modeled using induced pluripotent stem cell (iPSC) technology. Neurological disorders are frequent targets of iPSC-disease modeling for its ability to generate in vitro disease-relevant cell types from the central nervous system, such as neurons and glial cells. Patientspecific iPSC-derived neural cells can recapitulate the phenotypes of these diseases, unveiling mechanisms and providing drug screening platforms for novel therapeutic targets. Here, we review the accomplishments and the current progress achieved in human neurological disorders by using iPSC modeling for Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis, duchenne muscular dystrophy, schizophrenia and autism spectrum disorders.